Search results for: Tomohiro Miyake

Items from 1 to 15 out of 15 results

article

Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer

Ami Hori, Masafumi Shimoda, Yasuto Naoi, Naofumi Kagara, more

Breast Cancer Research > 2019 > 21 > 1 > 1-18

Background Trastuzumab is a drug that targets the receptor tyrosine kinase HER2 and is essential for the treatment of HER2-positive breast cancer. Resistance to the drug leads to severe consequences, including disease recurrence, tumor enlargement, and metastasis. We hypothesized that trastuzumab treatment might be associated with phenotypic switching in HER2-positive breast cancer cells (BCCs), enabling...

article

Prognostic value of tumor cell DNA content determined by flow cytometry using formalin-fixed paraffin-embedded breast cancer tissues

Hiroki Kusama, Masafumi Shimoda, Tomohiro Miyake, Tomonori Tanei, more

Breast Cancer Research and Treatment > 2019 > 176 > 1 > 75-85

Purpose The use of formalin-fixed paraffin-embedded (FFPE) tumor tissues in flow cytometry (FCM)-based determination of tumor cell DNA content is more complicated than the use of fresh-frozen tissues. This study aimed to accurately measure tumor cell DNA content from FFPE tissues by separating tumor cells from stromal cells through FCM and investigating its prognostic impact. Methods We separately...

article

Drainage of Tumor-Derived DNA into Sentinel Lymph Nodes in Breast Cancer Patients

Yukiko Miyamura, Naofumi Kagara, Tomohiro Miyake, Tomonori Tanei, more

Pathology & Oncology Research > 2019 > 25 > 4 > 1635-1643

Circulating tumor DNA (ctDNA) is released from cancer cells by apoptosis or other mechanisms, and as tumor tissue contains both blood and lymphatic vessels, ctDNA can spread to local lymph nodes (LNs). We aimed to detect the tumor-derived free DNA in metastasis-free LNs in patients with breast cancers harboring the PIK3CA-H1047R mutation. One hundred twenty-three patients were evaluated and the PIK3CA-...

article

Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC

Seiichi Imanishi, Yasuto Naoi, Kenzo Shimazu, Masafumi Shimoda, more

Breast Cancer Research and Treatment > 2019 > 174 > 3 > 627-637

Purpose This study aimed to elucidate the clinicopathological characteristics of breast tumors with homologous recombination deficiency (HRD) and the sensitivity to neoadjuvant paclitaxel followed by fluorouracil, epirubicin, and cyclophosphamide (P-FEC). Methods Tumor biopsy samples obtained before P-FEC from 141 patients with stages II–III breast cancer including the luminal (n = 76), luminal-HER2...

article

PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer

Ako Matsushita Ohara, Yasuto Naoi, Kenzo Shimazu, Naofumi Kagara, more

Breast Cancer Research and Treatment > 2019 > 173 > 3 > 533-543

Purpose There is an urgent need for the development of a predictor of response to chemotherapy for ER-positive breast cancer which is less chemosensitive than for ER-negative breast cancer in order to avoid unnecessary chemotherapy. In the present study, intrinsic subtyping by PAM50 was evaluated for its ability to predict a response to chemotherapy. Patients and Methods For this study, 124 patients...

article

Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients

Ryo Tsunashima, Yasuto Naoi, Kenzo Shimazu, Naofumi Kagara, more

Breast Cancer Research and Treatment > 2018 > 171 > 1 > 33-41

Purpose Prediction models for late (> 5 years) recurrence in ER-positive breast cancer need to be developed for the accurate selection of patients for extended hormonal therapy. We attempted to develop such a prediction model focusing on the differences in gene expression between breast cancers with early and late recurrence. Methods For the training set, 779 ER-positive breast cancers treated...

article

Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing

Nanae Masunaga, Naofumi Kagara, Daisuke Motooka, Shota Nakamura, more

Breast Cancer Research and Treatment > 2018 > 167 > 1 > 49-58

Purpose We aimed to develop a highly sensitive method to detect ESR1 mutations in cell-free DNA (cfDNA) using next-generation sequencing with molecular barcode (MB–NGS) targeting the hotspot segment (c.1600–1713). Methods The sensitivity of MB–NGS was tested using serially diluted ESR1 mutant DNA and then cfDNA samples from 34 patients with metastatic breast cancer were analyzed with MB–NGS. The...

article

Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing

Takehiro Yanagawa, Naofumi Kagara, Tomohiro Miyake, Tomonori Tanei, more

Breast Cancer Research and Treatment > 2017 > 163 > 2 > 231-240

Purpose Liquid biopsy using digital PCR (dPCR) has been widely used for the screening of ESR1 mutations, since they are frequently identified in the hotspot. However, dPCR is limited to the known mutations. Therefore, we aimed to analyze the utility of next-generation sequencing (NGS) to discover novel ESR1 mutations. Methods Whole exon sequencing of the ESR1 gene using NGS was performed in 16 primary...

article

Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women

Yoshimasa Miyagawa, Tomohiro Miyake, Ayako Yanai, Keiko Murase, more

Breast Cancer > 2015 > 22 > 4 > 399-405

Background The impact of body mass index (BMI) on the risk of postmenopausal estrogen receptor (ER)-positive breast cancers has been well documented. However, the mechanism for the impact of BMI on the etiology of luminal A and luminal B subtypes has not yet been identified. Methods We analyzed associations between BMI and breast cancers stratified by immunohistochemically defined intrinsic subtypes,...

article

C4.4A highly expressed in HER2-positive human breast cancers may indicate a good prognosis

Tomohiro Miyake, Takashi Ito, Ayako Yanai, Natsuko Inoue, more

Breast Cancer > 2015 > 22 > 4 > 366-373

Background The aim of our study was to investigate the association of C4.4A expression in breast tumors with both patients’ clinicopathological characteristics and outcomes in order to clarify the significance of C4.4A in breast cancer. Methods Primary breast cancer patients (n = 125, stage I–III) who had undergone breast mastectomy or breast-conserving surgery at our hospital between 2005 and 2011...

article

Impact of closed-system drug transfer device on exposure of environment and healthcare provider to cyclophosphamide in Japanese hospital

Tomohiro Miyake, Takuya Iwamoto, Manabu Tanimura, Masahiro Okuda

SpringerPlus > 2013 > 2 > 1 > 1-7

In spite of current recommended safe handling procedures, the potential for the exposure of healthcare providers to hazardous drugs exists in the workplace. A reliance on biological safety cabinets to provide total protection against the exposure to hazardous drugs is insufficient. Preventing workplace contamination is the best strategy to minimize cytotoxic drug exposure in healthcare providers....

article

GSTP1 expression predicts poor pathological complete response to neoadjuvant chemotherapy in ER‐negative breast cancer

Tomohiro Miyake, Takahiro Nakayama, Yasuto Naoi, Noriaki Yamamoto, more

Cancer Science > 103 > 5 > 913 - 920

The purpose of the present study was to investigate the association of glutathione S‐transferase P1 (GSTP1) expression with resistance to neoadjuvant paclitaxel followed by 5‐fluorouracil/epirubicin/cyclophosphamide (P‐FEC) in human breast cancers. The relationship of GSTP1 expression and GSTP1 promoter hypermethylation with intrinsic subtypes was also investigated. In this study, primary breast cancer...

article

Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay

Noriaki Yamamoto, Takahiro Nakayama, Masahiro Kajita, Tomohiro Miyake, more

Breast Cancer Research and Treatment > 2012 > 132 > 1 > 165-173

Aberrant promoter methylation of genes is a common molecular event in breast cancer. Thus, DNA methylation analysis is expected to be a new tool for cancer diagnosis. In this article, we have established a new, high-performance DNA methylation assay, the one-step methylation-specific polymerase chain reaction (OS-MSP) assay, which is optimized for analyzing gene methylation in serum DNA. The OS-MSP...

article

Indication for sentinel lymph node biopsy for breast cancer when core biopsy shows ductal carcinoma in situ

Tomohiro Miyake, Kenzo Shimazu, Hiroshi Ohashi, Tetsuya Taguchi, more

The American Journal of Surgery > 2011 > 202 > 1 > 59-65

The use of sentinel lymph node biopsy (SLNB) for ductal carcinoma in situ (DCIS) is controversial.A total of 103 primary breast cancer patients who were diagnosed with DCIS by needle biopsy preoperatively and underwent initial SLNB were analyzed retrospectively.No sentinel nodal metastasis was detected in 66 patients with the final diagnosis of DCIS. However, 2 (5.4%) of 37 patients with invasive...

article

Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer

Shigeyuki Tamura, Hirofumi Miki, Kaoru Okada, Tomohiro Miyake, more

International Journal of Clinical Oncology > 2008 > 13 > 6 > 536-540

Background There is no standard treatment for peritoneal dissemination from gastric cancer. A novel combination chemotherapy has been introduced for patients with advanced gastric cancer with peritoneal metastasis. Methods This pilot study was performed on four patients to confirm safety and efficacy. They were diagnosed with unresectable gastric cancer with severe peritoneal dissemination by staging...

Filter options

Publication date

Set your own date range

INFONA - science communication portal

Search results for: Tomohiro Miyake

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options